Payment overview · 2025
General Payments
$485.29
19 reported records · 12 companies
Healthcare provider profile · identity verified
Albert Odili Boyd, MD
Allopathic & Osteopathic Physicians|Family Medicine · DESOTO, TX · NPI 1679548721
Verified facts
What the public records show
CMS Open Payments records show Albert Odili Boyd, MD received $485.29 in general payments during 2025 across 19 reported records.
Galderma Laboratories, L.P. accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 308 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $125.48 | 25.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $111.81 | 23.0% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.34 | 7.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.80 | 7.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.24 | 7.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.09 | 5.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.49 | 4.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.21 | 4.4% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.55 | 3.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.86 | 3.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.45 | 3.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.97 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $485.29 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $111.81 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $111.81 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.80 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.80 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.24 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.24 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 90 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 90 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
57 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
76 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
90 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
308 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1141 | 249 |
| Amlodipine Besylate | Amlodipine Besylate | 676 | 159 |
| Furosemide | Furosemide | 599 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 58 |
| Losartan Potassium | Losartan Potassium | 344 | 87 |
| Metformin Hcl | Metformin Hcl | 339 | 81 |
| Donepezil Hcl | Donepezil Hcl | 322 | 49 |
| Trazodone Hcl | Trazodone Hcl | 317 | 57 |
| Divalproex Sodium | Divalproex Sodium | 316 | 56 |
| Eliquis | Apixaban | 308 | 41 |
| Lisinopril | Lisinopril | 280 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 272 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 256 | 68 |
| Mirtazapine | Mirtazapine | 248 | 58 |
| Famotidine | Famotidine | 236 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 235 | 63 |
| Carvedilol | Carvedilol | 232 | 60 |
| Gabapentin | Gabapentin | 232 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 221 | 44 |
| Pregabalin | Pregabalin | 209 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 192 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 188 | 41 |
| Levetiracetam | Levetiracetam | 188 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 185 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 181 | 31 |
| Memantine Hcl | Memantine Hcl | 175 | 25 |
| Sertraline Hcl | Sertraline Hcl | 163 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 162 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 62 |
| Hydralazine Hcl | Hydralazine Hcl | 147 | 49 |
| Buspirone Hcl | Buspirone Hcl | 146 | 32 |
| Alendronate Sodium | Alendronate Sodium | 139 | 40 |
| Jardiance | Empagliflozin | 134 | 21 |
| Simvastatin | Simvastatin | 131 | 25 |
| Finasteride | Finasteride | 128 | 22 |
| Montelukast Sodium | Montelukast Sodium | 124 | 26 |
| Nifedipine Er | Nifedipine | 124 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 119 | 25 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 105 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 36 |
| Celecoxib | Celecoxib | 103 | 28 |
| Potassium Chloride | Potassium Chloride | 97 | 23 |
| Ezetimibe | Ezetimibe | 93 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 17 |
| Ozempic | Semaglutide | 90 | 24 |
| Rybelsus | Semaglutide | 90 | 21 |
| Allopurinol | Allopurinol | 83 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 83 | 32 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 81 | 16 |
| Prednisone | Prednisone | 81 | 64 |
| Meloxicam | Meloxicam | 77 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 75 | 27 |
| Lactulose | Lactulose | 73 | 30 |
| Omeprazole | Omeprazole | 68 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 67 | 19 |
| Risperidone | Risperidone | 64 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 17 |
| Metformin Hcl Er | Metformin Hcl | 61 | 16 |
| Olanzapine | Olanzapine | 61 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 59 | 19 |
| Spironolactone | Spironolactone | 59 | 18 |
| Topiramate | Topiramate | 58 | 14 |
| Linzess | Linaclotide | 57 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 12 |
| Latanoprost | Latanoprost | 55 | suppressed |
| Glipizide | Glipizide | 54 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 52 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 52 | 13 |
| Megestrol Acetate | Megestrol Acetate | 52 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 17 |
| Albuterol Sulfate | Albuterol Sulfate | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Baclofen | Baclofen | 48 | 11 |
| Farxiga | Dapagliflozin Propanediol | 48 | 14 |
| Tramadol Hcl | Tramadol Hcl | 48 | 17 |
| Trulicity | Dulaglutide | 46 | 12 |
| Vascepa | Icosapent Ethyl | 46 | 13 |
| Cilostazol | Cilostazol | 44 | suppressed |
| Gemtesa | Vibegron | 44 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | suppressed |
| Lamotrigine | Lamotrigine | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 37 |
| Lacosamide | Lacosamide | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 31 |
| Sucralfate | Sucralfate | 42 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 38 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Torsemide | Torsemide | 34 | suppressed |
| Cefdinir | Cefdinir | 33 | 24 |
| Ipratropium Bromide | Ipratropium Bromide | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Brilinta | Ticagrelor | 31 | suppressed |
| Calcitriol | Calcitriol | 31 | suppressed |
| Humulin R | Insulin Regular, Human | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 27 |
| Methocarbamol | Methocarbamol | 31 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 19 |
| Novolog Flexpen | Insulin Aspart | 28 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Travoprost | Travoprost | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 13 |
| Azithromycin | Azithromycin | 23 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 16 |
| Glucagen | Glucagon | 22 | 12 |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 18 | suppressed |
| Ramelteon | Ramelteon | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 14 |
| Naproxen | Naproxen | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Acetylcysteine | Acetylcysteine | 13 | suppressed |
| Ertapenem | Ertapenem Sodium | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Fulvestrant | Fulvestrant | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 12 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $485.29 · 19 records | Galderma Laboratories, L.P. | AIRSUPRA, AUSTEDO XR, BREZTRI, Korlym, MOUNJARO, NUZYRA, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, VYNDAQEL, Veozah, XHANCE, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error